君合盟生物启动“重组A型肉毒毒素治疗成人上肢痉挛状态”临床III期试验，并完成首例患者入组

Core Viewpoint - Junhe Alliance Biopharmaceuticals has made significant progress with its recombinant type A botulinum toxin for treating upper limb spasticity post-stroke, having received approval for its Phase III clinical trial from the National Medical Products Administration [2][4]. Group 1: Clinical Development - The Phase III clinical trial is led by Professor Li Fang from Fudan University Huashan Hospital and Professor Jin Lingjing from Shanghai Yangzhi Rehabilitation Hospital, marking a breakthrough in this treatment area [2]. - The Phase III trial for the use of recombinant type A botulinum toxin in treating moderate to severe glabellar lines has also been initiated at Peking University First Hospital [4]. Group 2: Company Overview - Junhe Alliance Biopharmaceuticals focuses on synthetic biology technology and aims to advance innovative recombinant protein drugs in endocrine, neurological treatments, and next-generation biomedical materials [4]. - The company is developing a range of products, including recombinant type A botulinum toxin, human growth hormone injections, long-acting growth hormone, and artificial dermis [4]. Group 3: Technological Advancements - The recombinant type A botulinum toxin is developed using genetic engineering, protein engineering, and structural biology, overcoming key technical barriers in recombinant expression and formulation processes [5]. - This product demonstrates significant advantages in purity, activity, and safety, positioning it as a potential upgrade to traditional botulinum toxin products [5]. Group 4: Market Impact - As one of the first companies globally to master the core technology of recombinant type A botulinum toxin, Junhe Alliance's advancement in the Phase III clinical trial is expected to reshape the competitive landscape of the botulinum toxin market [6].